CasNo.202189-78-4,Powder Bilastine CAS 202189-78-4,(202189-78-4) Suppliers

1 Gram	FOB Price:USD 95.0000 -100.0000

Min.Order :1 Gram
Purity: 99%
Payment Terms : T/T,

Keywords

Bilastine 202189-78-4 CAS 202189-78-4

Quick Details

Appearance:white powder
Application:Animal Pharmaceuticals
PackAge:carton boc
ProductionCapacity:1000000|Kilogram|Month
Storage:cool and dry
Transportation:ship,fly

Superiority:

Hebei Mojin Biotechnology Co., Ltd,Our business covers more than 30 countries, most of the big customers come from Europe, America and other countries in the world, we can guarantee the quality and price. In recent decades, with the efforts of all employees, we have established many cooperative companies in shandong, henan, guangdong and other places. Our corporate purpose is based on the market, enhance the strength, take the road of scientific and environmental sustainable development, relying on the country. Technology r & d center, increase the investment in r & d, based on the domestic market, expand the international market, manufacturing quality products, sincere service to the society, into a modern, ecological, scientific and technological enterprise world.

Adenosine triphosphate can be used in the disease caused by tissue injury and activity reduction of ecto enzyme , including heart failure, carditis, miocardial infarction, cerebral arteriosclersis, coronary sclerosis, progressive muscular atrophy , cerebral hemorrhage , chronic hepatitis, cirrhosis of liver and hearing handicap, etc.

Details:

Product Detailed

Product Name:Bilastine
CAS:202189-78-4
MF:C28H37N3O3
MW:463.61
EINECS:
Mol File:202189-78-4.mol
Melting point:202 °C
Boiling point:639.1±55.0 °C(Predicted)
Density 1.16±0.1 g/cm3(Predicted)
pka4.40±0.10(Predicted)

Description
Bilastine, a potent and selective histamine H1 receptor antagonist, was approved in Europe in 2010 for the treatment of allergic rhinoconjunctivitis (AR) and urticaria (hives or skin rash). The original synthesis of bilastine involves alkylation of 2-piperidinyl-1H-benzimidazole with a phenethyltosylate, the para position of which is substituted with a dimethyloxazoline moiety serving as a masked carboxylic acid group. Alkylation of the benzimidazole nitrogen with 2-chloroethyl ethyl ethers followed by unmasking of the oxazoline moiety with sulfuric acid provided bilastine.
In two major clinical trials, bilastine was effective at relieving allergic rhinitis as assessed by measuring the severity of nasal (obstruction, rhinorrhea, itching, sneezing) and nonnasal (ocular itching, tearing, ocular redness, itching of ears, and/or palate) symptoms.
UsesBilastine is a novel, nonsedating H1-antihistamine developed for symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.
UsesLabelled Bilastine. It is a novel, nonsedating H1-antihistamine developed for symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.